European Pharmaceutical Review

FEBRUARY 8, 2023

GlobalData predicts Bristol-Myers Squibb’s Breyanzi and Gilead’s Yescarta are set to have high annual sales in the forecast period. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Peak sales are anticipated to reach $1.3 billion in 2031.

Labelling 96

Labelling Compounding 96

Express Pharma

APRIL 13, 2023

Mishlawi, who has been with Hikma for more than 26 years over two separate stints, was instrumental in the growth and global expansion of the group’s injectables business into a market-leading position. Edits by EP News Bureau) The post Riad Mishlawi named as next CEO of Hikma Pharma appeared first on Express Pharma.

91

91

Express Pharma

SEPTEMBER 14, 2023

LIC has sold two per cent of its holding in Sun Pharma for Rs 4,699 crore via open market sale. Edits by EP News Bureau) The post LIC sells over two per cent stake in Sun Pharma for Rs 4,699 cr appeared first on Express Pharma. It also informed that the shares were sold at an average price of Rs 973.80

52

52

pharmaphorum

OCTOBER 12, 2021

Sales were $20 million and $0.5 Gocovri could see its sales momentum rise following its approval for a second indication by the FDA earlier this year. per share subject to Gocovri meeting sales targets. per share subject to Gocovri meeting sales targets. million, respectively, in the second quarter of this year.

97

97

Express Pharma

AUGUST 31, 2023

CanSino begun researching mRNA technology in 2018 and has built a facility in Shanghai that can produce up to 200 million doses a year, giving it the capacity to provide similar services to other companies, CanSino’s CEO and co-founder Xuefeng Yu told a news agency in an interview. On Wednesday, it reported a gross loss of 776.5

Vaccines 111

Vaccines Immunity Immunization 111

pharmaphorum

JUNE 20, 2022

The rumour was first published in the Wall Street Journal, which suggests that a takeover is just one option on the table, along with a marketing deal that would bind the two companies together without the risk of antitrust issues holding up or blocking a merger. It says Merck has hesitation about whether a deal could make it through FTC.

104

104

pharmaphorum

DECEMBER 12, 2022

billion ($3.6bn) in annual sales from Tepezza (teprotumumab), a treatment for the painful autoimmune condition thyroid eye disease (TED). J&J soon pulled out, but the news resulted also in an increased market value of €20.9 Californian biotech Amgen’s own market value is circa €141.7 Under Rule 8.3(a)

104

104

pharmaphorum

JUNE 1, 2022

GlaxoSmithKline is due to complete the split from its consumer health decision – now renamed Haleon – next month, with a listing for the new company on the London Stock Exchange set for 18 July. A listing on the New York Stock Exchange will follow shortly, according to the pharma group.

Vaccines 104

Vaccines 104

European Pharmaceutical Review

NOVEMBER 29, 2023

This step is important as these countries are key markets for pharmaceuticals manufacturing. Based on data on sales/value-based shares from various companies for APIs and Chemicals, India and China are estimated to account for up to half of materials for medicines, the Sustainable Markets Initiative (SMI) noted.

Pharmaceutical Manufacturing 86

Pharmaceutical Manufacturing 86

pharmaphorum

MARCH 3, 2022

DarioHealth has beefed up its sales and marketing channels as well as its range of digital health products thanks to a $30 million strategic alliance with drugmaker Sanofi. Erez Raphael.

Diabetes 91

Diabetes 91

PharmaShots

MAY 26, 2023

Shots: Akebia will receive $10M up front, ~$100M in commercial milestones for rights to Vafseo in the EU & Australia along with royalty up to 30% of net sales. Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

40

40

PharmaShots

JUNE 19, 2023

Shots: Biomm to get an exclusive right to distribute & market BAT2206 in Brazil & will be responsible for filing the dossier in Brazil. Your go-to media platform for customized news ranging for multiple indications. BAT2206 was approved in Brazil for active PsA in adults as monotx.

Biosimilars 40

Biosimilars 40

PharmaShots

JUNE 5, 2023

a right of 1st negotiation for new indications of NRX-101 & new products containing D-cycloserine + antidepressant/antipsychotic Ref: Nrxpharma | Image: Alvogen PharmaShots! Your go-to media platform for customized news ranging for multiple indications. The agreement incl. The agreement incl.

40

40

PharmaShots

APRIL 25, 2023

anniversary of closing, ~$450M in additional sales-based milestones, based on annual sales of $175M & $200M and total net sales over 5yr. Shots: Lilly will receive $500M in cash at closing, ~$125M upon 1yr. Baqsimi is the first nasally administered glucagon for sev.

Diabetes 40

Diabetes 40

pharmaphorum

NOVEMBER 2, 2022

GSK now expects sales to grow between 8% and 10% at constant exchange rates this year, up from its previous prediction of 6% to 8%, with an operating profit of 15%-17% versus 13%-15%. billion (around $8.9 billion) against consensus forecasts of around £7.3 Operating profit was up 18% to £2.6 May decision on RSV vaccine.

Vaccines 98

Vaccines 98

pharmaphorum

MARCH 15, 2022

In return, it will get a royalty on sales if the new version gets approved. That may not prove to be a good investment, given the news this week that bempeg failed a phase 3 trial in melanoma as a combination therapy with Bristol-Myers Squibb’s Opdivo (nivolumab).

97

97

European Pharmaceutical Review

FEBRUARY 3, 2023

The CDMO’s nine facilities use cGMP -compliant technologies, including the new site for producing sterile injectable drug products. The HPAPI market A 2022 market report showed that due to the small volumes required for dosage, small-scale providers are also gaining importance.

Dosage 94

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 94

PharmaShots

MAY 5, 2023

Shots: Kinoxis will receive an up front & research support, ~$181M in milestones along with royalties on future Boehringer Ingelheim product sales. Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Compounding 40

Compounding 40

pharmaphorum

OCTOBER 20, 2020

Huge demand for ventilators and patient monitors spurred third quarter sales for Royal Philips, the company announced. The Dutch health technology group reported sales of €4.98bn, a 10% year-over-year growth. Sales were down 3%, to €1.97bn compared to a 9% dip in Q2.

Hospitals 104

Hospitals 104

PharmaShots

MAY 8, 2023

in sales milestones, and a fixed fee for each carton of Inbrija supplied to Chance. Your go-to media platform for customized news ranging for multiple indications. Shots: Acorda will receive $2.5M up front, ~$6M in near-term milestones, $3M upon regulatory approval, ~$132.5M

40

40

PharmaShots

APRIL 26, 2023

Spectrum’s combined assets & commercial infrastructure will accelerate Rolvedon’s launch for patients' benefit & drive further growth The combination of Assertio’s Omni-Channel digital sales capabilities & Rolvedon's in-person commercial team will enhance market access & growth across all products Ref: Globenewswire (..)

56

56

pharmaphorum

MAY 27, 2021

The approval is good news for Myovant’s partner Pfizer too, as the big pharma agreed a $4.2 The two companies share marketing rights to relugolix products in North America, while Pfizer has exclusive rights elsewhere.

Labelling 98

Labelling 98

PharmaShots

MARCH 29, 2023

Shots: Covant to receive $10M up front and will be eligible for ~$471M in additional milestones along with royalties on global sales The companies collaborated to develop novel small-molecule immunotherapy targeting ADAR1 for cancer patients & can be combined with other immunotherapies to enhance their efficacy Covant will be responsible for the (..)

40

40

European Pharmaceutical Review

JANUARY 25, 2023

To control dissemination of contaminated medicines, the World Health Organization calls on: Regulators to: Detect and remove from circulation in their respective markets any substandard medical products identified in the WHO medical alerts as potential causes of deaths and disease. NEWS: What can we learn from contamination control failures?

95

95

Pharma Marketing Network

JULY 13, 2023

When it comes to marketing your pharma business on Facebook, you may be wondering whether you should boost a post or create an ad. Placement: Your boosted post can appear in the News Feed, in the right column, or in Messenger. Your ad can appear in a variety of places, such as the News Feed, the Audience Network, or Instagram.

98

98

pharmaphorum

FEBRUARY 21, 2022

It’s a key moment for the two companies, as expansion into HER2-low breast cancer has been held up as a key requirement for Enhertu (trastuzumab deruxtecan) if it is to achieve its multibillion-dollar sales expectations. billion to Daiichi Sankyo if all the ADC’s development and sales objectives are achieved.

Chemotherapy 131

Chemotherapy Labelling 131

Fuld & Company Blog

DECEMBER 8, 2023

Although battery revenues only grew by 3% from Q2 to Q3, gross profit from battery sales rose to 24% in Q3, from 18% in Q2 2023 and 10% in 2022! Who said the green energy market is less profitable than the old hydrocarbon market! If true, this is big news, as heavy trucking is huge polluter, and warrants keeping a close eye on.

52

52

PharmaShots

MARCH 28, 2023

is currently being evaluated in a P-III study, expected to enroll patients (n=602) at 190 clinical sites in 17 countries Ref: PR Newswire | Image: OncoVent Related News:- Macomics Signs a Worldwide Drug Discovery Collaboration Agreement with Ono to Discover and Develop Macrophage-Targeting Antibody Therapy for Cancer

40

40

Express Pharma

JULY 5, 2023

The patent expiry of Amneal’s Rytary, an oral ER capsule formulation of levodopa, is anticipated in 2028, which will inevitably shrink its sales. But should IPX203 receive regulatory approval could help maintain Amneal’s presence in the PD market.

97

97

pharmaphorum

JANUARY 29, 2021

The post-marketing safety study showed that Xeljanz (tofacitinib) – used to treat rheumatoid arthritis (RA) – was associated with a higher rate of heart attacks and cancer than a TNF inhibitor in patients aged over 50 with underlying cardiovascular risk factors. Now, a study designed to prove its safety has achieved the opposite.

Labelling 135

Labelling 135

PharmaShots

APRIL 3, 2023

in additional development, regulatory & commercial milestones along with royalties on net sales for both ADC assets BioNTech received exclusive licenses from DualityBio for 2 ADC assets (DB-1303 & DB-1311) directed against targets expressed in a broad range of human cancers & will obtain commercial rights globally (excl.

40

40

Fuld & Company Blog

APRIL 5, 2024

Difficulty in differentiating amidst market competition. From deal origination and marketing to execution, relationship nurturing and outreach, leveraging R&A solutions has become a key ingredient to their success. Strategies to achieve this include: Regular publication of market updates and thought leadership.

Packaging 52

Packaging 52

pharmaphorum

DECEMBER 10, 2021

Already scrambling to refile its obeticholic acid (OCA) drug for non-alcoholic steatohepatitis (NASH) after the FDA rejected it last year, Intercept Pharma was hoping for more luck in Europe, but has now withdrawn its EU marketing application. Shares in Intercept slipped around 15% after it announced the news.

Packaging 98

Packaging 98

pharmaphorum

FEBRUARY 22, 2021

AZ’s share price ticked downwards after the announcement that it will stop marketing Imfinzi, a PD-L1 class immunotherapy, for previously treated adult patients with advanced or metastatic bladder cancer. The news will come as a blow for AZ, where Imfinzi has been an important component of the company’s cancer portfolio.

52

52

European Pharmaceutical Review

JANUARY 24, 2023

HUTCHMED will receive $400 million upfront as well as up to $730 million on meeting regulatory, development and commercial sales milestones. This is in addition to royalties on net sales. Fruquintinib is a new oral, highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, 2 and 3.

52

52

pharmaphorum

AUGUST 7, 2020

Pharma’s reputation has soared due to the COVID-19 pandemic – but coronavirus is starting to bite companies’ sales. Find out more in our roundup of the biggest R&D, market access and digital stories from the past week. Meanwhile, Bayer’s Q2 sales were down 2.5% to just over €10 billion, with pharma falling 8.8%

Nursing Homes 104

Nursing Homes Vaccines Immunity Immunization 104

pharmaphorum

JANUARY 17, 2022

In recent years it has successfully integrated the Novartis consumer health portfolio and the Pfizer portfolio, which resulted in annual sales of £9.6 However, amid news of the proposals, GSK’s share price was up almost 5% on Monday morning, while Unilever shares fell by as much as 7.3% billion in 2021. in London.

116

116